Quantitative determination of c-erbB-2 in human breast tumours: Potential prognostic significance of low values

被引:28
作者
Koscielny, S [1 ]
Terrier, P [1 ]
Daver, A [1 ]
Wafflart, J [1 ]
Goussard, J [1 ]
Ricolleau, G [1 ]
Delvincourt, C [1 ]
Delarue, JC [1 ]
机构
[1] Federat Ctr Lutte Contre Canc, Grp Biopathol Tissulaire & Mol, F-75654 Paris 13, France
关键词
breast tumours; c-erbB-2; prognostic factors;
D O I
10.1016/S0959-8049(97)10069-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this prospective multicentric study was to quantify the c-erbB-2 protein and investigate its relationship with DNA amplification and with various prognostic parameters of breast cancer. A total of 1062 primary operable human breast tumours were collected from six French anticancer centres. The c-erbB-2 protein was measured using an enzymoimmunoassay using two monoclonal antibodies directed against the extracellular domain of the protein. The results were expressed in arbitrary units/mg membrane protein (AU) after adjustment for the anticancer centre. A significant association was found between the dosage of the protein and DNA amplification (P = 0.0001). A value of 200 AU was found to maximise sensibility and specificity and was chosen as a cut-off for overexpression. Significant associations were found between c-erbB-2 values and oestrogen receptor (ER) (P = 0.01), progesterone receptor (PgR) (P = 0.0001) and histological grading (P = 0.01). The extreme high values (above the mean plus one standard deviation, S.D.) were significantly more numerous in ER- (P = 10(-16)), PgR(-) (P = 10(-14)) and grade III (P = 10(-8)) tumours. The extreme low values (below the mean minus one S.D.) were significantly more numerous in ER- (P = 10(-9)) and PgR(-) (P = 0.02) tumours. This prospective study confirms that high c-erbB-2 protein values are linked to poor prognostic factors and shows for the first time that low values are also Linked to hormone receptor negative tumours, suggesting that these low values might also have a negative prognostic significance. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:476 / 481
页数:6
相关论文
共 42 条
[21]  
RUSSELL KS, 1992, CANCER RES, V52, P6624
[22]   IS THE NEGATIVE PROGNOSTIC VALUE OF HIGH ESTROGEN-RECEPTOR (ER) LEVELS IN POSTMENOPAUSAL BREAST-CANCER PATIENTS DUE TO A MODIFIED ER GENE-PRODUCT [J].
SANCHOGARNIER, H ;
DELARUE, JC ;
MOURIESSE, H ;
CONTESSO, G ;
MAYLEVIN, F ;
GOTTELAND, M ;
MAY, E .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (11) :1851-1855
[23]  
*SAS I, 1989, SAS STAT US GUID VER, V2
[24]   THE NEU ONCOGENE - AN ERB-B-RELATED GENE ENCODING A 185,000-MR TUMOR-ANTIGEN [J].
SCHECHTER, AL ;
STERN, DF ;
VAIDYANATHAN, L ;
DECKER, SJ ;
DREBIN, JA ;
GREENE, MI ;
WEINBERG, RA .
NATURE, 1984, 312 (5994) :513-516
[25]  
SINGLETON TP, 1992, PATHOL ANNU, V27, P165
[26]   STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER [J].
SLAMON, DJ ;
GODOLPHIN, W ;
JONES, LA ;
HOLT, JA ;
WONG, SG ;
KEITH, DE ;
LEVIN, WJ ;
STUART, SG ;
UDOVE, J ;
ULLRICH, A ;
PRESS, MF .
SCIENCE, 1989, 244 (4905) :707-712
[27]   HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].
SLAMON, DJ ;
CLARK, GM ;
WONG, SG ;
LEVIN, WJ ;
ULLRICH, A ;
MCGUIRE, WL .
SCIENCE, 1987, 235 (4785) :177-182
[28]   HER-2 NEU ONCOGENE PROTEIN AND PROGNOSIS IN BREAST-CANCER [J].
TANDON, AK ;
CLARK, GM ;
CHAMNESS, GC ;
ULLRICH, A ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) :1120-1128
[29]   Use of a polyclonal antibody for the determination of the prognostic value of c-erbB-2 protein over-expression in human breast cancer [J].
Terrier, P ;
Mouriesse, H ;
Loridon, B ;
Gotteland, M ;
MayLevin, F ;
Delarue, JC .
ACTA ONCOLOGICA, 1996, 35 (01) :23-30
[30]   SHORT RECURRENCE-FREE SURVIVAL ASSOCIATED WITH HIGH ESTROGEN-RECEPTOR LEVELS IN THE NATURAL-HISTORY OF POSTMENOPAUSAL, PRIMARY BREAST-CANCER [J].
THORPE, SM ;
CHRISTENSEN, IJ ;
RASMUSSEN, BB ;
ROSE, C .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (07) :971-977